Global pedigree of new director boosts Crescendo Biologics
Crescendo Biologics, a Cambridge drug developer of novel, targeted T-cell engaging therapeutics, has appointed the highly respected Igor Matushansky, MD as a non-executive director.
Igor is currently chief medical officer and global head of R & D at Hookipa Biotech AG (Hookipa), a clinical stage immuno-therapy biotech. Prior to Hookipa, he was the global head of translational development for oncology at Daiichi Sankyo, where he focused on early oncology therapeutic programmes, strategy and development.
Prior to that, he was at Novartis where he was the global head for clinical and scientific development at its Gene & Cell Therapy Unit as well as a global clinical program lead within Novartis’ Oncology Translational Medicine Unit.
Before moving into the pharmaceutical industry in 2010, Igor was a Professor at the Columbia University Medical Center where he ran an independent laboratory and clinic focusing on the molecular biology, translational opportunities and clinical trials in sarcomas.
Currently Igor is an Adjunct Professor of Medical Oncology at Columbia University.
Crescendo chairman Kevin Johnson, said: “With this appointment, Crescendo has further strengthened its expertise in clinical development and its position at the forefront of next generation immuno-oncology therapy companies.”
• PHOTOGRAPH SHOWS: Igor Matushansky